What are AMRX's recent SEC filings?
Amneal Pharmaceuticals filed an amendment to its Form 8-K to include the historical financial statements of Kashiv BioSciences, LLC and pro forma financial information related to its previously completed acquisition of Kashiv. The acquisition itself was originally reported on August 10, 2026.
View full filing details →Amneal Pharmaceuticals completed the acquisition of Kashiv BioSciences for $375 million in cash and 28.9 million shares of Class A common stock, with potential contingent payments of up to $350 million upon achievement of regulatory milestones and royalty payments over 12 years.
View full filing details →Amneal Pharmaceuticals filed its quarterly report (10-Q) for the period ending June 30, 2026, providing financial results and operational updates.
View full filing details →Has AMRX ever done a stock split?
No stock splits are recorded for AMRX.
What is AMRX's share float?
Get Real-Time AMRX Intelligence
SEPT X-Ray combines SEC filings with price targets, support/resistance levels, and smart money tracking — updated every 30 minutes.
Try SEPT X-Ray Free